You may also like

From Structural Biology to Structuring Companies: Deb Palestrant on The Long Run
Creating a New Class of Medicines: John Maraganore on The Long Run
Gene Editing Therapies Delivered In Vivo: Ensoma’s Emile Nuwaysir on The Long Run
The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen